1. Home
  2. IOVA vs WVE Comparison

IOVA vs WVE Comparison

Compare IOVA & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IOVA
  • WVE
  • Stock Information
  • Founded
  • IOVA 2007
  • WVE 2012
  • Country
  • IOVA United States
  • WVE Singapore
  • Employees
  • IOVA N/A
  • WVE N/A
  • Industry
  • IOVA Biotechnology: Biological Products (No Diagnostic Substances)
  • WVE Biotechnology: Pharmaceutical Preparations
  • Sector
  • IOVA Health Care
  • WVE Health Care
  • Exchange
  • IOVA Nasdaq
  • WVE Nasdaq
  • Market Cap
  • IOVA 3.0B
  • WVE 2.4B
  • IPO Year
  • IOVA N/A
  • WVE 2015
  • Fundamental
  • Price
  • IOVA $8.18
  • WVE $13.67
  • Analyst Decision
  • IOVA Strong Buy
  • WVE Strong Buy
  • Analyst Count
  • IOVA 9
  • WVE 10
  • Target Price
  • IOVA $23.33
  • WVE $21.30
  • AVG Volume (30 Days)
  • IOVA 7.2M
  • WVE 1.3M
  • Earning Date
  • IOVA 11-07-2024
  • WVE 11-12-2024
  • Dividend Yield
  • IOVA N/A
  • WVE N/A
  • EPS Growth
  • IOVA N/A
  • WVE N/A
  • EPS
  • IOVA N/A
  • WVE N/A
  • Revenue
  • IOVA $90,858,000.00
  • WVE $53,610,000.00
  • Revenue This Year
  • IOVA $13,827.67
  • WVE N/A
  • Revenue Next Year
  • IOVA $183.70
  • WVE N/A
  • P/E Ratio
  • IOVA N/A
  • WVE N/A
  • Revenue Growth
  • IOVA 12751.20
  • WVE N/A
  • 52 Week Low
  • IOVA $4.44
  • WVE $3.50
  • 52 Week High
  • IOVA $18.33
  • WVE $16.74
  • Technical
  • Relative Strength Index (RSI)
  • IOVA 32.59
  • WVE 50.96
  • Support Level
  • IOVA $9.31
  • WVE $14.95
  • Resistance Level
  • IOVA $10.86
  • WVE $16.71
  • Average True Range (ATR)
  • IOVA 0.71
  • WVE 1.04
  • MACD
  • IOVA -0.37
  • WVE -0.28
  • Stochastic Oscillator
  • IOVA 1.48
  • WVE 14.72

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Share on Social Networks: